Ocular Therapeutix Raises $475M to Advance Retinal Therapies

Ocular Therapeutix, Inc., a biopharmaceutical company, has announced it has secured $475,000,000 in a recent funding round from investors. This significant capital infusion is intended to support the company's ongoing efforts to redefine the retina experience across drug development, treatment, and outcomes. The investment underscores confidence in Ocular Therapeutix's pipeline and its proprietary technology. The company's leading investigational candidate is AXPAXLI™ (also known as OTX-TKI), an axitinib hydrogel administered by intravitreal injection. This candidate, built on Ocular’s proprietary ELUTYX™ technology, targets retinal diseases. AXPAXLI™ is currently undergoing Phase 3 clinical trials for wet age-related macular degeneration (wet AMD). Beyond wet AMD, the investigational treatment also shows potential applications across other serious retinal conditions, including non-proliferative diabetic retinopathy (NPDR) and diabetic macular edema (DME). This substantial financial raise is poised to significantly bolster Ocular Therapeutix's strategic objectives. The company plans to use the funds for growth initiatives, which are expected to include the acceleration of its clinical development programs, particularly for AXPAXLI™. It also provides capital to expand research and development capabilities and prepare for potential future commercialization activities. The successful completion of this funding round positions Ocular Therapeutix, Inc. to advance its mission of delivering innovative treatments for retinal diseases. The company is focused on progressing its pipeline and leveraging its ELUTYX™ technology to address unmet medical needs, anticipating continued growth and impact in the biopharmaceutical landscape.